David.Hainsworth

“Economic & Personal Pinboard” - Not Personal Advice | Assume Personal Interest In All Securities Mentioned.

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL announces the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).

This represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways.

Learn more: https://t.co/EnJcFaj53A

[David.Hainsworth @DavidHainsworth]

A very exciting year ahead for Algorae and our shareholders.

The commercial opportunity and the calibre of our partners in India is exceptional.

@algoraepharma

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (ASX: 1AI) has completed a productive week in India, supporting the Company’s focus on commercial execution and partner engagement.

The visit provided valuable on-the-ground insight across manufacturing capability, supply chain readiness and strategic alignment as Algorae advances its capital-light pharmaceutical commercialisation model.

Initiatives like this help strengthen the foundations for disciplined execution and support Algorae’s broader pathway toward commercial growth.

Keep up to date for more: https://t.co/DYgOhcz2aN

#ASX #1AI #Algorae #Pharma #Commercialisation

[Algorae Pharmaceuticals @algoraepharma]

Algorae (ASX: #1AI) has strengthened its balance sheet with a $3.99M capital raise.

The funding supports growth across AlgoraeRx commercialisation and the AlgoraeOS R&D pipeline, with pro forma cash of ~$5.56M plus access to a $3.0M debt facility.

View the announcement: https://t.co/RHwqRojwYJ

[Algorae Pharmaceuticals @algoraepharma]

Algorae (ASX: 1AI) is advancing validation of its AI-driven drug discovery platform, with a second screening program now underway with Peter MacCallum Cancer Centre.

program will assess 24 high-priority drug combination candidates across four cancer cell lines, with key preclinical data expected within six months.

This marks another important step in translating AlgoraeOS predictions into biological validation and supporting future development and commercial pathway discussions.

🔔View the full announcement: https://t.co/2la7d9MqBE

#1AI #ASXnews

[David.Hainsworth @DavidHainsworth]

@algoraepharma We’re delighted to welcome David Gulland to the board. His deep industry expertise will be a great strategic and operational asset for the company.

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharma (#ASX: #1AI) finalises Commercial Licence & Supply Agreement with Cadila Pharmaceuticals to launch two news generic cardiovascular & metabolic medicines in Australian and New Zealand #ASXNews #Cardiology

Read here: https://t.co/12aQlYcKrX

[Incannex Healthcare Inc. @ASX_IHL]

Fast Track designation brings $IXHL closer to our goal of delivering a convenient, effective oral therapy for patients living with OSA. Our team looks forward to continued collaboration with the @US_FDA in 2026 as we advance IHL-42X toward patients who urgently need new options.

[David.Hainsworth @DavidHainsworth]

@australian “Appearing to wrestle a gun?” You just posted the footage where this brave man is literally seen risking his life to intervene in a dangerous situation that could easily cost his own life while potentially saving the lives of others. I pray he’s okay and applaud his bravery.

[Algorae Pharmaceuticals @algoraepharma]

AI-enabled pharmaceutical company Algorae Pharma (#ASX: #1AI) is delighted to announce receipt of in silico (supercomputer) drug synergy predictions from AlgoraeOS v2 - 90 combination drug targets predicted for further evaluation. #ASXNews #AI
Read here: https://t.co/cyI05dJ4Er

[Algorae Pharmaceuticals @algoraepharma]

AI-enabled pharmaceutical company Algorae Pharma (#ASX: #1AI) has received a cash refund of $384,466.78 from the ATO under the R&D Tax Incentive program.

#ASXNews #Biotech #Pharmaceuticals #Tech #AI

[David.Hainsworth @DavidHainsworth]

Congratulations to the @algoraepharma team and our partners at @UNSW and @CSIRO

$1AI #ASX

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharma (#ASX : #1AI) is delighted to announce independent validation of its #AI-powered AlgoraeOS drug combination prediction platform. #ASXNews #biotech #pharma #tech

Read here: https://t.co/Bkup4vO3uA

[Incannex Healthcare Inc. @ASX_IHL]

#IncannexHealthcare announces that the @US_FDA has granted Fast Track designation for IHL-42X, $IXHL's oral fixed-dose combination product candidate for the treatment of #obstructivesleepapnea (#OSA).

Full press release here: https://t.co/vm8Cwo6k9A

[David.Hainsworth @DavidHainsworth]

Delighted to partner with global pharmaceutical leader, @drreddys on this distribution agreement. @algoraepharma #ASX #1AI $1AI

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharma (#ASX: #1AI) is delighted to announce it has entered into a distribution agreement with global pharmaceutical leader Dr. Reddy’s Laboratories Ltd (#NYSE: $RDY) to supply the chemotherapy medicine Capecitabine into the Australian health market.
Read here: https://t.co/xdiopwbAcV

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals Limited (#ASX: #1AI) is delighted to announce the launch of AlgoraeOS Ver. 2 - a major upgrade to Algorae’s #AI drug discovery platform.

Read here: https://t.co/mQyFO7SGtb

[David.Hainsworth @DavidHainsworth]

Algorae Pharmaceuticals Driving Expansion with Innovation and Commercialisation

⁦@algoraepharma⁩ #1AI $1AI https://t.co/sD0hm2c3yj

[David.Hainsworth @DavidHainsworth]

A significant period of progress for Algorae. Congratulations to the team, particularly Vishal Shah who has been instrumental in the execution of our commercial partnerships. We look forward to David Gulland joining us as COO. @algoraepharma

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (#ASX Code: #1AI) #ASXnews: Algorae September 2025 Quarterly Activities Report and Appendix 4C Cash Flow Statement. #AI #biotech #FDA #TGA
Read here: https://t.co/VQCXyMl9tG

[David.Hainsworth @DavidHainsworth]

We are pleased to partner with Sakar Healthcare Ltd on this exclusive commercial licensing agreement.

Congratulations to the @algoraepharma team. #1ai #ASX

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (#ASX: #1AI) is delighted to announce an exclusive commercial licensing agreement with Sakar Healthcare (NSE: $SAKAR) to launch five (5) generic oncology medicines into Aus/NZ markets with addressable market A$10M/annum.

Read here: https://t.co/nXgyObWxjC

[David.Hainsworth @DavidHainsworth]

Commentary on our AI drug development platform, AlgoraeOS. @algoraepharma #1AI

[Algorae Pharmaceuticals @algoraepharma]

The AI drug discovery opportunity Australia must seize

https://t.co/TnsL7xvKyN

[Incannex Healthcare Inc. @ASX_IHL]

#IncannexHealthcare is pleased to report positive data from its Phase 2 #clinicaltrial of PSX-001 (formerly Psi-GAD), a psilocybin-assisted #psychotherapy treatment for Generalised Anxiety Disorder (GAD).

Read more: https://t.co/kd1SIn9znG

$IXHL #ClinicalTrials #IXHL

[Incannex Healthcare Inc. @ASX_IHL]

#IncannexHealthcare announced that its Board of Directors has authorized a share repurchase program for up to $20 million of $IXHL's outstanding shares of common stock.

Read the full press release here: https://t.co/chN997XXZG

#IXHL